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Background: Canine mammary tumors (CMTs) are the most common type of cancer found in female dogs.
Establishment and evaluation of tumor cell lines can facilitate investigations of the biological mechanisms of cancer.
Different cell models are used to investigate genetic, epigenetic, and cellular pathways, cancer progression, and
cancer therapeutics. Establishment of new cell models will greatly facilitate research in this field. In the present
study, we established and characterized two new CMT cell lines derived from a single CMT.
Results: We established two cell lines from a single malignant CMT specimen: DTK-E and DTK-SME. Morphologically,
the DTK-E cells were large, flat, and epithelial-like, whereas DTK-SME cells were round and epithelial-like. Doubling
times were 24 h for DTK-E and 18 h for DTK-SME. On western blots, both cell lines expressed cytokeratin AE1,
vimentin, cytokeratin 7 (CK7), and heat shock protein 27 (HSP27). Moreover, investigation of chemoresistance
revealed that DTK-SME was more resistant to doxorubicin-induced apoptosis than DTK-E was. After xenotransplantation,
both DTK-E and DTK-SME tumors appeared within 14 days, but the average size of DTK-SME tumors was greater than
that of DTK-E tumors after 56 days.
Conclusion: We established two new cell lines from a single CMT, which exhibit significant diversity in cell morphology,
protein marker expression, tumorigenicity, and chemoresistance. The results of this study revealed that the DTK-SME cell
line was more resistant to doxorubicin-induced apoptosis and exhibited higher tumorigenicity in vivo than the DTK-E
cell line. We anticipate that the two novel CMT cell lines established in this study will be useful for investigating the
tumorigenesis of mammary carcinomas and for screening anticancer drugs.
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Mammary gland carcinomas are the most common neo-
plasms in both women and female dogs [1,2]. Clinical evi-
dence has shown that approximately 50% of canine
mammary tumors (CMTs) are diagnosed as malignant in
dogs [3]. CMTs possess epidemiological, clinicopathologi-
cal, and biochemical characteristics similar to those of hu-
man breast carcinomas [4,5]. Therefore, CMTs have been
considered an appropriate and valid model for human
breast cancer studies for more than three decades [6].* Correspondence: ychang@gate.sinica.edu.tw; yslai@niu.edu.tw
3Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan
1Department of Biotechnology and Animal Science, National Ilan University,
Yilan, Taiwan
Full list of author information is available at the end of the article
© 2014 Lai et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Tumor cell lines have been widely used for in vitro re-
search, and have proven to be a particularly useful tool
for genetic analyses. Previous characterizations of tumor
cell lines have shown that they are also excellent models
for studying the biological mechanisms underlying can-
cer [7]. The use of tumor cell lines has increased our
knowledge of the deregulated genes and signaling path-
ways involved in cancer [8,9]. Furthermore, original cell
models have been developed to test anticancer drugs
[8,10-12]. Tumor cell lines continue to be used in the
development of new therapies [7,11,13], and also provide
an alternative to direct transplantation of tumors in ani-
mals for testing chemotherapeutics [14].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer research. Different cell models are used to inves-
tigate genetic, epigenetic, and cellular pathways [7];
proliferation deregulation, apoptosis, and cancer pro-
gression [9]; and identification of potential molecular
markers [15], as well as to screen and characterize can-
cer therapeutics [11,16]. The findings reported from
tumor cell lines are typically extrapolated to in vivo hu-
man tumors [15]. Thus, many biomedical and pharma-
ceutical companies have recognized the importance of
tumor cell lines as models for drug testing and transla-
tional studies [8].
In the present study, we established and characterized
two new CMT cell lines, termed DTK-E and DTK-SME.
These two cell lines exhibited significant diversity in cell
morphology, protein marker expression, tumorigenicity,
and chemoresistance. Our results suggest that the two
established cell lines might constitute a useful experi-
mental model for investigating the tumorigenesis of
mammary carcinomas and for screening potential anti-
cancer drugs.
Results
Morphological analysis of established cell lines
After over 100 passages, two CMT cell lines, DTK-E
and DTK-SME, were established from canine mammary
carcinomas. When adhered to a culture plate, DTK-E
cells exhibited a large, flat, epithelial-like morphology
(Figure 1A), while DTK-SME cells presented a rounded,
epithelial-like morphology (Figure 1B). Of the two estab-
lished cell lines, only DTK-SME cells possessed pile up
(Figure 1B). Transmission electron micrographs showed
that both DTK-E and DTK-SME cells exhibited high
nuclear-cytoplasmic ratios and large nucleoli (Figure 2).
Biological analysis of established cell lines
Alterations in the biological properties of the two CMT
cell lines were monitored during their establishment.
During the first 10 passages, 50% fetal bovine serum
(FBS) was required to maintain cell growth. After 10
passages, the percentage of FBS in the medium wasFigure 1 Phase contrast micrographs of CMT cells derived from ma
epithelial-like characteristics; (B) DTK-SME cells displayed rounded, epith
position of pile up.gradually reduced. After 100 passages, 5% FBS was suffi-
cient to support the growth of both CMT cell lines. In
addition, contact inhibition was only significant during
the first 35 passages, and was completely lost after 50
passages (data not shown). During establishment of the
two CMT cell lines, we also determined the doubling
time. The final doubling times for DTK-E and DTK-
SME cells were 24 h and 18 h, respectively (Figure 3).
Expression profile of CMT genes and proteins
We used western blot analysis with specific antibodies to
investigate the individual protein expression profiles of
the two CMT cell lines (Table 1). Both CMT cell lines
expressed the low-molecular weight cytokeratin AE1 and
vimentin, cytokeratin 7 (CK7), and heat shock protein 27
(HSP27) (Figure 4A, B). In addition, DTK-SME exhibited
a higher level of HSP27 expression than DTK-E cells. In
reverse transcription-polymerase chain reaction (RT-PCR)
assays, the CK7 and HSP27 gene expression profiles were
the same as their respective protein expression profiles;
both DTK-E and DTK-SME cells expressed CK7 and
HSP27 genes (Figure 4C).
Tumorigenicity of established CMT cell lines
We performed xenografts to examine the tumorigenicity
of the two CMT cell lines. At passage 100, each cell line
was injected subcutaneously into five 8-week-old athy-
mic mice (BALB/c nu/nu). A tumor mass was first ob-
served at the injection site in all mice injected with
DTK-E and DTK-SME cells at 1 week post-injection; at
8 weeks, the DTK-SME and DTK-E groups exhibited
masses of 1.8–2.2 cm and 0.5–0.7 cm in diameter, re-
spectively (Figure 5).
Doxorubicin (DOX)-induced dose-dependent growth
suppression, apoptosis, and caspase-3 activation in
CMT cells
Next, we investigated the susceptibility of the two CMT
cell lines to DOX. Cells were treated with DOX and cell
growth and apoptosis were analyzed at 24 h, 48 h, and
72 h. We found that DOX (1000 nM) was able tolignant tumor tissue. (A) DTK-E cells displayed mostly large, flat,
elial-like features and possessed pile up. Arrowhead indicates
Figure 2 Transmission electron micrographs of CMT cell lines. Intracellular morphology of (A) DTK-E and (B) DTK-SME cells. Images are
representative of 20 random sections per cell line. Scale bars = 2 μm.
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and time-dependent manner in DTK-E cells, but not in
DTK-SME cells (Figures 6 and 7). Further quantitative
analysis revealed that 72-h exposures to 100 nM and
1000 nM DOX resulted in 2% and 58% mortality, re-
spectively, in DTK-E cells (Figure 6). In addition, DOX
(1000 nM) treatment caused DNA fragmentation in
DTK-E cells at 72 h (Figure 7A). In contrast, no DNA
fragmentation was observed at 72 h in DTK-SME
cells. Because activation of caspase-3 is a hallmark of
apoptosis, we examined caspase-3 activation in DOX-
treated (1000 nM) CMT cells (Figure 7B). DOX in-
duced the time-dependent cleavage of procaspase-3
into its active caspase-3 form in DTK-E cells, but not
in DTK-SME cells.Figure 3 Growth curves of DTK-E and DTK-SME cell lines.
Symbols represent the mean of triplicate samples and the data are
expressed as the mean ± SE.Discussion
In the present study, we established and characterized
two new CMT cell lines derived from a single malignant
tumor: DTK-E and DTK-SME. DTK-E cells showed a
large, flat, epithelial-like morphology, while DTK-SME
cells showed a rounded epithelial-like morphology.
Both DTK-E and DTK-SME cells exhibited a high
nuclear-cytoplasmic ratio, which is often associated
with malignancy in tumor cells. Consistent with this
finding, xenografts of injected DTK-E and DTK-SME
cells developed into prominent solid tumors within
2 weeks, and the tumor mass of DTK-SME was larger
than that of DTK-E after the 8-week study.
The human breast contains a branching ductal net-
work composed of two epithelial cell types: an inner
layer of polarized luminal epithelial cells and an outer
layer of myoepithelial cells. Breast cancer arises mainly
in the luminal epithelial compartment of the terminal
duct lobular units [17,18]. Several proteins have been
identified as important cell markers for investigating
tumor pathophysiology. Cytokeratins (CKs) are critical
markers of epithelial differentiation [19]. The distribu-
tion of CKs is tissue-specific, and this feature facilitates
the determination of tumor origin [20-22]. One low-
molecular weight cytokeratin subtype, CK7, is a marker of
luminal epithelial cells in both human and canine mam-
mary tissues [23]. In a study of 435 cases, expression ofTable 1 Overview of the sources and dilutions of the
primary antibodies used in this study
Antibody Source Clone Dilution
AE1 NeoMarkers AE1 (mouse monoclonal) 1:1000
Vimentin NeoMarkers V-9 (mouse monoclonal) 1:1000
CK 7 Santa Cruz 5F282 (mouse monoclonal) 1:1000
Hsp27 GeneTex GTX25579 (rabbit polyclonal) 1:1000
Caspase 3 NeoMarkers CPP (rabbit polyclonal) 1:1000
β-actin Sigma AC-15 (rabbit polyclonal) 1:5000
Figure 4 Expression profiles of protein markers in the DTK-E and DTK-SME cell lines. (A) Western blot analysis of total proteins in cell
lysates. Lane 1, pre-stained protein marker; Lane 2, DTK-E; Lane 3, DTK-SME. (B) Protein expression in DTK-E and DTK-SME cell lines detected with
antibodies to vimentin, cytokeratin 7 (CK7), low-molecular weight cytokeratin AE1, and heat shock protein 27 (HSP27). (C) RT-PCR analysis of CK7
and HSP27 gene expression in DTK-E and DTK-SME cell lines. β-actin served as an internal control.
Figure 5 Tumor growth curves of DTK-E and DTK-SME cells in
tumorigenicity tests. Cells were subcutaneously injected into
nude mice and monitored for 8 weeks. The tumor volumes were
estimated every 2 weeks and calculated, and the data are expressed
as the mean ± SE.
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thelial neoplasms [24]. Other studies have also reported a
high incidence of CK7 (56%) in canine mammary gland
carcinomas [25]. In this study, we showed that DTK-E and
DTK-SME expressed CK7 and possessed high tumorigen-
icity. These results suggest that the DTK-E and DTK-SME
cell lines could have originated directly from the tumor
cells in the surgical specimen.
Vimentin is an intermediate filament protein expressed
in mesenchymal cells [26]. Vimentin expression in inva-
sive breast carcinomas is generally considered to indicate
the epithelial-to-mesenchymal transition or myoepithelial
histogenesis. Vimentin-positive breast tumors have been
described as mostly malignant, highly invasive, and che-
moresistant [27]. Interestingly, the DTK-E and DTK-SME
cell lines established in this study were vimentin-positive
and displayed tumorigenicity in mice.
HSP27 is a member of the small heat shock protein
family of molecular chaperones. It plays an essential role
in protein folding and protects cells from stress-induced
damage [28,29]. In general, the healthy canine (and hu-
man) mammary gland exhibits little or no HSP27 ex-
pression [30-32]. In human breast cancer tumor cells,
Figure 6 Effects of DOX on DTK-E and DTK-SME cell proliferation. Cells were treated with escalating doses of DOX (1, 10, 100, and 1000 nM)
and incubated for 24 h, 48 h, and 72 h. Cell viability was determined every 24 h. Cell numbers were averaged over triplicate samples, and the
data are expressed as the mean ± SE.
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cancer progression [33], increased anchorage-independent
growth [34], increased invasiveness [35,36], and resistance
to chemotherapeutic drugs [34,37-39]. In patients, ele-
vated expression of HSP27 in human breast cancer tissues
has been shown to indicate poor prognosis and a low
survival rate [40,41]. Therefore, increased expression of
HSP27 in human breast cancers might affect the prognosis
and treatment outcome [42].
DOX is an antitumor drug that can promote tumor
cell apoptosis. Currently, DOX is widely used to treat a
broad spectrum of cancers. In vitro studies of cancer
cells have shown that HSP27 expression protects against
apoptosis and confers resistance to DOX [38,43,44].
Interestingly, we also observed an association between
increased HSP27 expression and resistance to DOX
(Figures 6 and 7). Indeed, HSP27 expression was ele-
vated in both the DTK-E and DTK-SME cell lines,although the expression level was higher in DTK-SME
cells. Accordingly, DTK-SME cells were more resistant
to DOX-mediated apoptosis and tumor masses were lar-
ger than those of DTK-E cells. The correlation between
HSP27 and CMT malignancy currently remains unclear;
thus, these two CMT cell lines with different tumorige-
nicities may serve as a valuable cell model for future
studies of the roles of HSP27 in tumorigenicity and
chemoresistance.
Conclusion
We established and characterized two new CMT cell
lines with diverse tumorigenic properties. DTK-E cells
were large, flat, and epithelial-like, while DTK-SME
cells showed a rounded epithelial-like morphology and
possessed pile up. Both DTK-E and DTK-SME cells
were vimentin+/AE1+/CK7+/HSP27+ and tumorigenic
in nude mice. These two cell lines also exhibited
Figure 7 DOX-induced apoptosis and caspase-3 activation in
DTK-E and DTK-SME cells. (A) Agarose gel electrophoresis of total
cellular DNA showed DOX-induced DNA fragmentation (apoptosis)
in CMT cells. Cells were incubated with 1000 mM DOX for 24 h,
48 h, and 72 h. M: DNA marker. (B)Western blots show DOX-induced
activation of caspase-3 in CMT cells. Cells were incubated with 1000
nM DOX for 24 h and 48 h.
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Based on their diverse malignancy, tumorigenicity,
protein marker profiles, and drug susceptibility, these
newly established CMT cell lines represent useful cell
models for basic tumor biology studies and for devel-




The tumor tissues used in this study were obtained from
client-owned dogs with the consents of the owners
acquired prior to sample collection. The handling of ani-
mals was practiced following a high standard of veterin-
ary care. A tumor specimen was surgically excised from
the mammary tissue of an 8-year-old mixed-breed fe-
male dog. Fresh neoplastic masses from the specimen
were placed in primary culture, and the remaining samples
were fixed in 10% formalin for histopathology. A histo-
logical examination confirmed the diagnosis of mammary
carcinoma. Tumor specimens consisted of highly prolifer-
ating, luminal epithelial and fibroblastic stromal cells; theyalso had glandular structures with irregular lumens em-
bedded in fibrous stroma.
Establishment of cell lines
A single tumor specimen was washed with RPMI 1640
medium (Sigma; St. Louis, MO, USA) that contained
500 IU/mL penicillin and streptomycin. The tissue was
minced with scissors and transferred to a 60-mm-
diameter tissue culture dish (Nunc; Waltham, MA USA)
containing 10 mL of 0.25% trypsin solution (0.25% tryp-
sin and 0.2% ethylenediaminetetraacetic acid [EDTA] in
phosphate-buffered saline [PBS]). The tissue suspension
was gently agitated with a magnetic stir bar at 4°C for
1 h. The resulting supernatant was transferred to a new
tube. An equal volume of complete RPMI 1640 medium,
containing 10% FBS (Hyclone Laboratories; Logan, UT,
USA) and 100 IU/mL penicillin and streptomycin was
added and mixed well. The mixture was centrifuged at
180 × g for 5 min, and the pelleted cells were resus-
pended in fresh, complete medium. The cells were then
seeded into 25-cm2 culture flasks and incubated with
complete medium at 37°C in a humidified atmosphere of
95% air and 5% CO2. Observations were performed daily
with a phase-contrast microscope. When cultured cells
reached 90% confluence, they were washed with 2 mM
EDTA in PBS, dispersed in the 0.25% w/v trypsin solu-
tion, and placed in a new flask at a density of 1 × 105
cells/mL. After 20 passages, cells were stored in RPMI
1640 medium containing 20% FBS and 10% dimethyl
sulfoxide (Sigma). In addition, at passage 20, different
cell types were subcloned from the parental cell line
with a limiting-dilution method.
Electron microscopy
After 100 passages, cultured CMT cells were harvested,
fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buf-
fer, and placed at 4°C overnight. After fixation, the cells
were treated with 1% osmium tetroxide at 4°C for 2 h,
washed in cacodylate buffer, dehydrated in graded acet-
one solutions, and embedded in Spur’s low-viscosity
resin. The embedded specimen was sectioned with a
Reichert-Jung Ultracut E ultramicrotome (Nussloch,
Germany), and the sections were stained with 2% uranyl
acetate (EMS; Fort Washington, PA, USA) in distilled
water for 1 min. Images were acquired with a JEOL JEM
2000 EXII transmission electron microscope (JEOL Ltd.;
Tokyo, Japan).
Growth assay
To investigate the growth of CMT cells, after 100 pas-
sages, 1 × 105 cells were seeded in 25-cm2 tissue culture
flasks and incubated in complete medium at 37°C. After
the cells were detached with trypsinization, they were
stained with trypan blue in triplicate flasks and counted
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calculated and recorded.
Western blot analysis
CMT cells were collected and lysed with 100 μL sample
buffer that contained 100 mM Tris–HCl buffer, pH 6.8, 4%
sodium dodecyl sulfate (SDS), 0.07% β-mercaptoethanol,
20% glycerol, and 0.2% bromophenol blue. The crude cell
lysate proteins were electrophoresed on a 12% SDS-
acrylamide gel and then stained with Coomassie Brilliant
Blue R-250 for protein profiling or transferred to polyvinyli-
dene fluoride membranes for western blot analysis. The
membranes were blocked with 5% skim milk, incubated
with primary antibodies (Table 1) for 2 h, and subsequently
incubated with alkaline phosphatase-conjugated secondary
antibodies. Membranes were developed with 5-bromo-4-
chloro-3-indolyl phosphate and 4-nitro-blue tetrazolium
chloride as substrates.
Total RNA isolation and RT-PCR
Total RNA was isolated from the cells using TRIzol re-
agent (Invitrogen; Paisley, Scotland, UK) according to
the manufacturer’s protocol. After digestion with RNase-
free DNase (New England Biolabs; Beverly, MA, USA),
2 μg of total RNA was reverse-transcribed into first-
strand cDNA using random primers according to the
Reverse Transcriptase Kit (Roche; Penzberg, Germany)
protocol. The PCR was carried out in a volume of
50 μL containing 2 μL cDNA, 0.5 μM forward primer,
0.5 μM reverse primer, 2.5 μM dNTP, 1× PCR buffer, and
2.5 U Taq DNA polymerase (Viogene; Taipei, Taiwan).
The primers for CK7 were as follows: Forward-5′- CA
GGTGCGCCTGAGCTCG-3′, Reverse-5′-GCGGTAGG
TGGCGATCTC-3′. PCR was carried out under the fol-
lowing conditions: 10 min at 95°C; 35 cycles of 1 min at
95°C, 1 min at 56°C, and 1 min at 72°C; and 10 min at
72°C. The primers for HSP27 were as follows: Forward-5′-
ATGACCGAGCGCCGAGTGCCC-3′, Reverse-5′-CTTG
GCTCCAGACTGCTCCGA-3′. PCR was carried out
under the following conditions: 5 min at 95°C; 35 cycles
of 45 s at 95°C, 45 s at 54°C, and 1 min at 72°C; and
10 min at 72°C. The primers for β-actin were as follows:
Forward-5′-CTGGGACGACATGGAGAA-3′, Reverse-
5′-GAGTACTTGCGCTCAGG-3′. PCR was carried
out under the following conditions: 5 min at 95°C; 35 -
cycles of 45 s at 95°C, 45 s at 55°C, and 45 s at 72°C;
and 10 min at 72°C. The PCR products were electro-
phoresed on a 1.2% agarose TAE-buffered gel and
stained with ethidium bromide.
Tumorigenicity
Animal handling and experimental procedures were
approved by the Institutional Animal Care and Use
Committee of National Ilan University (Referencenumber: No. 103-10). After 100 passages, CMT cells
(1 × 107) were subcutaneously inoculated into the
backs of 8-week-old athymic BALB/c nude mice. Five
nude mice were used to test each cell line. Physio-
logical data of the mice were recorded weekly, and
tumor volumes were estimated every 14 days and cal-
culated as described previously [45]. Mice were sacri-
ficed 56 days after inoculation. Results are expressed as
the mean tumor volume.
Susceptibility to doxorubicin
After 100 passages, CMT cells (1 × 105) were seeded into
25-cm2 tissue culture flasks in triplicate. After 24-h in-
cubation, cells were treated with the antitumor drug
DOX for 72 h. Mock control cells were treated with
water. After the treatment, cells were trypsinized, har-
vested, stained with 0.4% trypan blue, and counted with
a hemocytometer under a light microscope. The average
number of cells in triplicate flasks was calculated and
recorded.
DNA ladder assay
After DOX (1000 nM) treatment, cells were collected
and lysed at 55°C for 1 h in 500 μL lysis buffer that con-
tained 100 mM NaCl, 10 mM Tris (pH 8.0), 25 mM
EDTA, 0.5% SDS, 200 μg/mL DNase-free proteinase K
(Sigma), and 50 μg/mL DNase-free RNase (Sigma). DNA
was extracted with phenol/chloroform, precipitated with
100% ethanol, and resuspended in double-distilled water.
DNA samples were then separated on l.6% agarose gels
and stained with ethidium bromide.
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